SANTA ROSA – Osseon Therapeutics named Gary Coughlen, CPA, as chief financial officer. Osseon specializes in alternative minimally invasive treatments for degenerative bone and joint disease.
Mr. Coughlen was most recently CFO of PolyRemedy Inc., a private-equity medical device firm focused on wound care management. Prior to that, he was CFO of Refractec Inc., a manufacturer and distributor of ophthalmic surgical devices, seeing the company's growth from three to 75 employees. He has a bachelor's in business administration from the University of Washington and an MBA from U.C. Berkeley.